175609-12-8

Basic information

• Product Name: (S)-(-)-3,4-dehydro-6-benzoyloxymethyl-2-thiopiperidinone
• Synonyms: (S)-(-)-3,4-dehydro-6-benzoyloxymethyl-2-thiopiperidinone
• CAS NO: 175609-12-8
• Molecular Weight: 247.318
• Mol File: 175609-12-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (S)-(-)-3,4-dehydro-6-benzoyloxymethyl-2-thiopiperidinone(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-(-)-3,4-dehydro-6-benzoyloxymethyl-2-thiopiperidinone(175609-12-8)
• EPA Substance Registry System: (S)-(-)-3,4-dehydro-6-benzoyloxymethyl-2-thiopiperidinone(175609-12-8)

Safety Data

• Hazardous Substances Data: 175609-12-8(Hazardous Substances Data)

Upstream product

• 1026229-00-4 (S)-2-Benzoyloxymethyl-6-oxo-piperidine-1-carboxylic acid tert-butyl ester 
• 1026261-78-8 (S)-2-Benzoyloxymethyl-6-oxo-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 175609-09-3 Benzoic acid (S)-6-oxo-piperidin-2-ylmethyl ester 
• 128726-47-6 (+)-(S)-6-hydroxymethyl-2-piperidinone 
• 98-88-4 benzoyl chloride 
• 175609-11-7 Benzoic acid (S)-6-oxo-1,2,3,6-tetrahydro-pyridin-2-ylmethyl ester 

Downstream Products

• 175702-33-7 (S)-(-)-3,4-dehydro-6-hydroxymethyl-2-thiopiperidinone 

Relevant articles and documents

Inhibition of mouse tumor metastasis with nojirimycin-related compounds

The antimetastatic activity of ten compounds structurally related to nojirimycin A was examined using a pulmonary metastatic model of mouse B16 melanoma. Nojirimycin B, deoxynojirimycin, D-gluco-δ-lactam, CP3068 and CP3069 are structural analogues of nojirimycin A, and showed potent or moderate antimetastatic activities. Nojirimycin A, nojirimycin B, deoxynojirimycin and D-gluco-δ-lactam showed potent or moderate inhibitory activities against α-glucosidase, β-glucosidase and β-mannosidase, but CP3068 and CP3069 in which the structures were related to D-gluco-δ-lactam showed no inhibitory activities. CP3041, CP3042, CP3043, CP3045 and CP3048 are analogues of sodium D-glucaro-δ-lactam (ND2001), a carboxy derivative of nojirimycin A, and showed potent or moderate antimetastatic activities. But no analogue was superior to ND2001 concerning with antimetastatic and anti-β-glucuronidase activities. CP3041 and CP3042 showed potent and moderate inhibitory activities against β-glucuronidase, respectively, but CP3043, CP3045 and CP3048 showed little or no activities.